405 results found for: T
- tyrosinase-related protein-1
- A recombinant peptide of the tyrosinase-related protein 1 (TRP1) used in vaccine therapy. Expressed by cells of melanocyte origin, TRP1 is an enzyme involved in the process that converts tyrosinase to melanin pigments. Vaccination with TRP1 may stimulate cytotoxic T cell responses to melanoma cells. Check for active clinical trials using this agent. (NCI Thesaurus)
- tyrosine kinase inhibitor OSI-930
- A selective thiophene-derived tyrosine kinase inhibitor with potential antineoplastic activity. Tyrosine kinase inhibitor OSI-930 inhibits stem cell factor receptor (c-Kit) and the vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of both tumor cell proliferation and tumor angiogenesis. Both c-Kit and VEGFR2 are overexpressed in a variety of cancers. Check for active clinical trials using this agent. (NCI Thesaurus)
- tyrosine kinase inhibitor XL228
- A synthetic molecule that targets multiple tyrosine kinases with potential antineoplastic activity. Tyrosine kinase inhibitor XL228 binds to and inhibits the activities of multiple tyrosine kinases, such as the insulin-like growth factor 1 receptor (IGF1R), Src tyrosine kinase, and Bcr-Abl tyrosine kinase. Blockade of these kinases may result in the inhibition of tumor angiogenesis, cell proliferation, and metastasis. In addition, this agent may be a potent inhibitor of the T315I mutant form of the Abl protein, which is associated with the resistance of chronic myelogenous leukemia (CML) to other tyrosine kinase inhibitors. IGF1R and Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis. Bcr-Abl translocation leads to constitutive activation of ABL kinase and is commonly associated with Philadelphia-positive acute lymphocytic leukemia (ALL). Check for active clinical trials using this agent. (NCI Thesaurus)
- Tysabri
- (Other name for: natalizumab)
- Tyzeka
- (Other name for: telbivudine)
No hay comentarios:
Publicar un comentario